Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab/Fludarabine Followed by Alemtuzumab in CLL/SLL
NCT00193466Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jan 2002
- Primary completion
- Jan 2007
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of alemtuzumab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Complete Response Rate. Started Jan 2002; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00193466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193466.